Skip to main content

Incyte to Present at Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March:

  • TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 am (EST)

  • Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 9:20 am (EDT) and

  • Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 8:30 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  258.58
-0.95 (-0.37%)
AAPL  341.27
+0.30 (0.09%)
AMD  605.53
+11.29 (1.90%)
BAC  53.96
-0.62 (-1.14%)
GOOG  349.52
+0.55 (0.16%)
META  762.50
+19.54 (2.63%)
MSFT  543.45
+2.30 (0.43%)
NVDA  228.52
+2.20 (0.97%)
ORCL  143.20
+5.81 (4.23%)
TSLA  375.23
-2.80 (-0.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.